Angiotensin-II receptor type Ia does not contribute to cardiac atrophy following high-thoracic spinal cord injury in mice
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
543 0
SM ISO690:2012
JARVE , Anne, FATIMUNNISA, Qadri, TODIRAŞ, Mihail, SCHMOLKE, Shirley, BADER, Michael. Angiotensin-II receptor type Ia does not contribute to cardiac atrophy following high-thoracic spinal cord injury in mice. In: Experimental Physiology, 2020, nr. 8(105), pp. 1316-1325. ISSN 0958-0670. DOI: https://doi.org/10.1113/EP088378
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Experimental Physiology
Numărul 8(105) / 2020 / ISSN 0958-0670 /ISSNe 1469-445X

Angiotensin-II receptor type Ia does not contribute to cardiac atrophy following high-thoracic spinal cord injury in mice

DOI:https://doi.org/10.1113/EP088378

Pag. 1316-1325

Jarve Anne12, Fatimunnisa Qadri1, Todiraş Mihail13, Schmolke Shirley1, Bader Michael1245
 
1 Max Delbrück Center for Molecular Medicine in the Helmholtz Association,
2 German Center for Cardiovascular Research,
3 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
4 Berlin School of Public Health, Charité-Universitätsmedizin, Berlin,
5 University of Lübeck
 
 
Disponibil în IBN: 30 septembrie 2020


Rezumat

New Findings: What is the central question of this study? What is the role of the renin–angiotensin system with angiotensin II acting via its receptor AT1a in spinal cord injury-induced cardiac atrophy? What is the main finding and its importance? Knockout of AT1a did not protect mice that had undergone thoracic level 4 transection from cardiac atrophy. There were no histopathological signs but there was reduced load-dependent left ventricular function (lower stroke volume and cardiac output) with preserved ejection fraction. Abstract: Spinal cord injury (SCI) leads to cardiac atrophy often accompanied by functional deficits. The renin–angiotensin system (RAS) with angiotensin II (AngII) signalling via its receptor AT1a might contribute to cardiac atrophy post-SCI. We performed spinal cord transection at thoracic level T4 (T4-Tx) or sham-operation in female wild-type mice (WT, n = 27) and mice deficient in AT1a (Agtr1a−/−, n = 27). Echocardiography (0, 7, 21 and 28 days post-SCI) and histology and gene expression analyses at 1 and 2 months post-SCI were performed. We found cardiac atrophy post-SCI: reduced heart weight, reduced estimated left ventricular mass in Agtr1a−/−, and reduced cardiomyocyte diameter in WT mice. Although, the latter as well as stroke volume (SV) and cardiac output (CO) were reduced in Agtr1a−/− mice already at baseline, cardiomyocyte diameter was even smaller in injured Agtr1a−/− mice compared to injured WT mice. SV and CO were reduced in WT mice post-SCI. Ejection fraction and fractional shortening were preserved post-SCI in both genotypes. There were no histological signs of fibrosis and pathology in the cardiac sections of either genotype post-SCI. Gene expression of Agtr1a showed a trend for up-regulation at 2 months post-SCI; angiotensinogen was up-regulated at 2 month post-SCI in both genotypes. AngII receptor type 2 (Agtr2) was up- and down-regulated at 1 and 2 months post-SCI in WT mice, respectively, and Ang-(1-7) receptor (Mas) at 1 and 2 months post-SCI. Atrogin-1/MAFbx and MuRF1, atrophy markers, were not significantly up-regulated post-SCI. Our data show that lack of AT1a does not protect from cardiac atrophy post-SCI.

Cuvinte-cheie
atrogenes, cardiac atrophy, renin–angiotensin system